Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2022-04-22 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is an invitation to an earnings conference call scheduled for April 28, 2022, to discuss operational and financial performance. It includes details about the call, speakers, dial-in numbers, and registration instructions. There is no actual financial data or results presented, only an announcement of the upcoming call. The document length is short (2598 characters) and it serves as a notice rather than a report or transcript. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, but since it is only an invitation, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the call. However, given the specific nature of the document as an invitation to an earnings call, the most appropriate classification is Call Transcript (CT) because it relates directly to the earnings call event, but since it is not the transcript itself, it is not CT. The best fit is Regulatory Filings (RNS) as a general announcement about the call. Confidence is high due to clear content and format.
2022-04-22 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about a forthcoming Board Meeting scheduled for 27th April 2022. The agenda includes consideration and approval of the Financial Results along with the Auditor Report for the financial year ended 31st March 2022. The document is an announcement of the meeting and the intended approval of financial results, not the financial results or auditor report themselves. It also mentions compliance with SEBI regulations and insider trading restrictions. The document length is short (1795 characters) and it serves as a notice rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice, rather than a full Annual Report (10-K) or Audit Report (AR).
2022-04-18 English
General updates
Regulatory Filings Classification · 95% confidence The document is a press release or announcement about Beta Drugs Ltd receiving regulatory approval from the Drug Controller General of India (DCGI) for a new drug, KABONIB. It discusses product launches, market strategy, and drug details but does not contain financial statements, earnings data, or detailed financial analysis. The document length is short (1760 characters) and is primarily an update on regulatory approval and product information rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings that require financial data or formal regulatory content. It is best classified as a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2022-04-12 English
General updates
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by Link Intime India Pvt. Ltd. under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It confirms the processing of dematerialisation requests for the quarter ended 31 March 2022, including acceptance/rejection of securities and compliance with SEBI circulars. The document is a regulatory compliance certificate related to securities processing and does not contain financial statements, management discussion, or detailed financial data. It is not an annual report, interim report, earnings release, or any other financial report. It is also not an announcement of a report but a compliance confirmation certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-04-11 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about the closure of the trading window for insiders due to the upcoming declaration of audited financial results for the fiscal year ended 31 March 2022. It references regulatory guidelines on insider trading and trading restrictions but does not contain any financial data or the actual financial results. The document is short (1373 characters) and serves as an announcement related to trading restrictions ahead of a financial report release. Therefore, it is not the financial report itself but an announcement related to regulatory compliance and trading restrictions. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-03-31 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to the National Stock Exchange of India Limited, providing clarification about a previous announcement regarding product launches and market plans. It does not contain financial statements, detailed financial data, or comprehensive report content. The length is only 1214 characters, which is quite short and indicative of an announcement or clarification rather than a full report. There is no indication of it being a financial report, audit, earnings release, or any other detailed filing. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement clarifying prior information submitted to the exchange.
2022-03-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.